Copertina

Tumour hepcidin levels as a biomarker for predicting response to immune checkpoint inhibition in advanced non‐small cell lung cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yuichiro Suzukawa, Masaki Yamamoto, Shuhei Teranishi, Sosuke Kubo, Makoto Kudo, Takeshi Kaneko
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Clinical and Translational Discovery
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours
di: Meghali Goswami, et al.
Pubblicazione: (2024)

A comprehensive analysis of the correlation between plasma cytokines/chemokines and tumor immune microenvironment signature influences the response of checkpoint inhibitors in advanced non‐small‐cell lung cancer
di: Van Hieu Mai, et al.
Pubblicazione: (2026)

Challenges and advances of immune checkpoint therapy
di: Lingyu Li, et al.
Pubblicazione: (2024)

Multi‐omics predictive model based on clinical, radiomic and genomic features for predicting the response of limited‐stage small cell lung cancer to definitive chemoradiotherapy
di: Li Li, et al.
Pubblicazione: (2024)

A subtype of cancer‐associated fibroblast expressing syndecan‐2 (SDC2) predicts survival and immune checkpoint inhibitor response in gastric cancer
di: Ji‐Yong Sung, et al.
Pubblicazione: (2024)

Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non‐small‐cell lung cancer
di: Yu Wang, et al.
Pubblicazione: (2024)

Distinct fibroblast subpopulations associated with bone, brain or intrapulmonary metastasis in advanced non‐small‐cell lung cancer
di: Ke Xu, et al.
Pubblicazione: (2024)

Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer
di: Ailing Cao, et al.
Pubblicazione: (2026)

Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy
di: Agnieszka Beata Malczewski, et al.
Pubblicazione: (2025)

Single‐cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non‐small‐cell lung cancer
di: Xiaoshen Zhang, et al.
Pubblicazione: (2024)

Multi‐omics molecular phenotyping reveals the potential mechanisms of chemotherapy response and resistance in small cell lung cancer
di: Ying Cheng, et al.
Pubblicazione: (2024)

The co‐location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non‐small cell lung cancer
di: Guangyu Fan, et al.
Pubblicazione: (2024)

scICB: A pan‐cancer database of human temporal immune checkpoint blockade therapy at single‐cell transcriptomic resolution
di: Fansen Ji, et al.
Pubblicazione: (2025)

Machine learning and radiomics for predicting efficacy of programmed cell death protein 1 inhibitor for small cell lung cancer: A multicenter cohort study
di: Pulin Li, et al.
Pubblicazione: (2024)

Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors
di: Saira Afzal, et al.
Pubblicazione: (2024)

Dissolved gases from pressure changes in the lungs elicit an immune response in human peripheral blood
di: Abigail G. Harrell, et al.
Pubblicazione: (2024)

Longitudinal metabolomic profiling unveils dynamic biomarkers for predicting immune recovery in HIV‐1 infection
di: Jiali Lv, et al.
Pubblicazione: (2025)

Pre‐existing CD95‐based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD‐L1 and TGFβ inhibition
di: Ngar Woon Kam, et al.
Pubblicazione: (2025)

In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
di: Linda Wanika, et al.
Pubblicazione: (2024)

CD81 promotes proliferation and predicts survival in lung squamous cell carcinoma
di: Ryu Kanzaki, et al.
Pubblicazione: (2026)

Engineered lung cell targeting and SLC7A11 siRNA expressing bacterial extracellular vesicles impair the progression of none‐small cell lung cancer
di: Xiao‐dan Wan, et al.
Pubblicazione: (2025)

Anti‐PF4 antibody inhibit proliferation of lung cancer cells without TP53 mutation by inducing apoptosis and cell cycle arrest
di: Mengjia Qian, et al.
Pubblicazione: (2025)

Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy
di: Kaixin Wu, et al.
Pubblicazione: (2024)

Multilayered precision regulation to induce robust CD8+ T‐cell immune responses
di: Yingyue Zeng, et al.
Pubblicazione: (2025)

Predictive circulating biomarkers of the response to anti‐PD‐1 immunotherapy in advanced HER2 negative breast cancer
di: Yuhan Wei, et al.
Pubblicazione: (2025)

Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre‐clinical models
di: Maria‐Danae Jessel, et al.
Pubblicazione: (2025)

Activated immune cells present a lung interstitial‐to‐airway/alveolar cross‐compartment sharing pattern in severe pneumonia
di: Yuean Zhao, et al.
Pubblicazione: (2026)

CXCR5 and TLR4 signals synergistically enhance non‐small cell lung cancer progression
di: Ji Hye Shin, et al.
Pubblicazione: (2024)

Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
di: Xuwen Lin, et al.
Pubblicazione: (2024)

Monocyte–macrophage dynamics as key in disparate lung and peripheral immune responses in severe anti‐melanoma differentiation‐associated gene 5‐positive dermatomyositis‐related interstitial lung disease
di: Jia Shi, et al.
Pubblicazione: (2025)

Interleukin‐11 promotes lung adenocarcinoma tumourigenesis and immune evasion
di: Cristina Cirauqui, et al.
Pubblicazione: (2025)

Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study
di: Luca Marzano, et al.
Pubblicazione: (2024)

Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion‐driven non‐small cell lung cancer
di: Antoine Desilets, et al.
Pubblicazione: (2024)

Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma‐like carcinoma
di: Yu‐Min Zhong, et al.
Pubblicazione: (2024)

Immune responsiveness in stable kidney transplantation patients: Complete inhibition of T‐cell proliferation but residual T‐cell activity during maintenance immunosuppressive treatment
di: Aliede E. in ’t Veld, et al.
Pubblicazione: (2024)

A comprehensive atlas of pediatric immune checkpoint inhibitors‐related adverse events: From real‐world pharmacovigilance data to mechanistic insights
di: Anqi Lin, et al.
Pubblicazione: (2025)

Identification of CENPM as a key gene driving adrenocortical carcinoma metastasis via physical interaction with immune checkpoint ligand FGL1
di: Cunru Zou, et al.
Pubblicazione: (2025)

Plasma amyloid beta biomarkers predict amyloid positivity and longitudinal clinical progression in mild cognitive impairment
di: Takuya Ataka, et al.
Pubblicazione: (2024)

Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival
di: Vahid Yaghoubi Naei, et al.
Pubblicazione: (2024)

Restoring expression of tumour suppressor PTEN by engineered circular RNA‐enhanced Osimertinib sensitivity in non‐small cell lung cancer
di: Haoran Li, et al.
Pubblicazione: (2024)